Diagnosing the decline in pharmaceutical R&D efficiency

By J. Scannell, Alex Blanckley, Helen Boldon, B. Warrington. Nature reviews. Drug discovery, 2012

1,886 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Economics and Econometrics, Public Health, Environmental and Occupational Health

View Paper: https://www.semanticscholar.org/paper/ef4416cc5e8f9e0776bf85be25d0f8e2b71102fb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

In Economics and Econometrics

In Public Health, Environmental and Occupational Health

Citations in the corpus

Discovery and resupply of pharmacologically active plant-derived natural products: A review (2015, background): “The obtained results, however, did not meet the expectations as evident in a declining number of new drugs reaching the market (David et al., 2015; Kingston, 2011; Scannell et al., 2012).”
A data-driven approach to predicting successes and failures of clinical trials (2016, background): “This is occurring despite improvements in all stages of the drug development pipeline (Scannell et al., 2012).”
Regulated cell death (RCD) in cancer: key pathways and targeted therapies (2022, background): “MOA is of great significance in evaluating the efficacy and toxicity of compounds.(376) A study found that altretamine is a new GPX4 inhibitor similar to sulfasalazine through the prediction-based MOA analysis of detecting mechanism of action by network dysregulation (demand) and combined with exper”
Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review (2012, background): “However, it is worth to note that looking only at the number of new drugs without considering their therapeutic value omits an important factor in the analysis (Austin, 2006; Overington et al., 2006; Chong & Sullivan, 2007; Bunnage, 2011; Edwards et al., 2011; Scannell et al., 2012).”
Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design (2023, background): “The global outbreak of COVID-19 has caused significant disruptions to various operations worldwide, including ongoing clinical trials (Chavda, et al, 2023).”
Artificial Intelligence for Clinical Trial Design. (2019, background): “Although pharma and biotechnology companies have continuously increased R&D investment for decades, the number of new drugs gaining regulatory approval per billion USD spent has halved approximately every 9 years [1].”
Systematic integration of biomedical knowledge prioritizes drugs for repurposing (2017, background): “mal strategy from both a business and public health perspective (Scannell et al., 2012).”